Novotech, a full-service international clinical contract research organization (CRO), is proud to announce its recognition as a U.S. Great Place to Work® certified company. This prestigious certification underscores Novotech’s commitment to fostering a flexible, inclusive, and innovative work environment, where every employee is empowered to contribute to the future of medical research.
The certification is based on direct feedback from employees, highlighting the strong culture of support and teamwork in Novotech’s U.S. offices. It also reflects the company’s dedication to ensuring both the professional and personal development of its team members.
Key reasons Novotech earned the Great Place to Work certification:
- A welcoming, inclusive, and diverse workplace culture.
- Opportunities for career advancement, continuing education, and learning.
- Emphasis on flexibility and work-life balance.
- A solution-oriented, team-based approach to delivering quality service to clients.
- Recognition and appreciation of individual and team contributions to the company’s success.
Angela Edwardson, Chief Human Resources Officer at Novotech, expressed her pride in the achievement: “Our employees are the heart of the company, and ensuring their satisfaction is our top priority. This certification validates our efforts to create an environment that promotes innovation, where every team member feels valued and appreciated.”
This U.S. certification also reflects Novotech’s global commitment to positive workplace culture. The company is now planning to extend this certification process to its offices worldwide, further cementing its reputation as an employer of choice across its global operations.
Edwardson added: “We are deeply grateful to our U.S. team for their participation in this process and to all Novotech employees for their dedication and hard work. We look forward to continuing to drive innovation and growth together on a global scale.”
About Novotech
Founded in 1997, Novotech is an international CRO specializing in partnerships with biotech and small to medium-sized pharmaceutical companies. It provides comprehensive services to accelerate the development of cutting-edge therapies across all stages of development.
Novotech has been recognized with numerous industry accolades, including the 2023 CRO Leadership Award, the Asia-Pacific Cell and Gene Therapy Clinical Trial Excellence Award, and the Asia-Pacific CRO Company of the Year Award. With over 3,000 employees across 34 global locations, Novotech is a trusted strategic partner, offering end-to-end services such as laboratory support, Phase I clinical centers, regulatory compliance, and expertise in more than 5,000 clinical projects, spanning Phase I to Phase IV trials and bioequivalence studies.
